Back to News
Market Impact: 0.22
Ironwood: Medicare Is Not The Problem I Thought It Was
Source: seekingalpha.com
Analyst InsightsHealthcare & BiotechCompany FundamentalsConsumer Demand & Retail
Ironwood Pharmaceuticals is rated Buy with a $5.25 fair-value estimate. LINZESS generated $143.74 per 30 capsules, near Medicare's projected 2027 price of $136. Sales rose 44%, but the increase was primarily price-driven, while underlying demand grew only 4% to 5%, limiting the strength of the operating-growth signal.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.28
Ticker Sentiment
IRWD0.32
More News
- Nvidia in talks to invest up to $10 billion in Anthropic IPO
- The inside story on the historic U.S.-Venezuela oil deal and how it will work
- Apollo in talks to buy J&J orthopedics unit for nearly $20 billion
- Exclusive-Nvidia in talks to invest in Anthropic’s mega IPO, sources say
- How Canadians are bracing for the impact of Trump’s trade war
- Rising petrol costs drive sharp inflation increase in US in August